



Greater Bay Area
International
Clinical Trial Institute
粵港澳大灣區國際臨床試驗所

粵港澳大灣區國際臨床試驗中心
Greater Bay Area International Clinical Trials Center



**PRESS RELEASE
FOR IMMEDIATE RELEASE**

GBAICTI, BAY TRIAL and Health Hope Pharma Sign MoU to Advance Clinical Trials and Biomedical Innovation in Hong Kong and the Greater Bay Area

(Hong Kong, 28 July 2026) – The Greater Bay Area International Clinical Trial Institute (GBAICTI), The Greater Bay Area International Clinical Trials Center (BAY TRIAL) and Health Hope Pharma (HHP) today signed a Memorandum of Understanding (MoU) to establish a strategic collaboration framework for advancing new drug development and conducting international multi-centre clinical trials in Hong Kong and across the wider Guangdong-Hong Kong-Macao Greater Bay Area (GBA).

Under the “One Institute One Center” framework, GBAICTI, established and wholly owned by the Hong Kong Special Administrative Region Government, and BAY TRIAL of the Shenzhen Municipality are dedicated to developing Hong Kong’s and GBA’s clinical trial ecosystem and facilitating multi-centre research across the region. HHP is a Hong Kong-headquartered, late clinical-stage oncology and ophthalmology biopharmaceutical company. Through this collaboration, the parties intend to jointly explore opportunities to accelerate the development of innovative therapeutics, while strengthening Hong Kong’s position as a regional hub for multi-centre clinical trials.

Key Areas of Collaboration

- **Clinical Research and Trials:** The parties will explore opportunities to collaborate in identifying, designing and conducting clinical trials in areas of mutual interest. Within this framework, GBAICTI and BAY TRIAL will work to facilitate connections between HHP and clinical research sites across Hong Kong and the GBA, in support of the broader development of GBA’s clinical trial ecosystem. HHP is the first Hong Kong-based biopharmaceutical company with late-stage clinical programmes to conduct multiple clinical studies in Hong Kong and across the GBA, including a Phase III MRCT with first patient enrolment targeted for the second half of 2026. Site preparatory work at multiple locations in Hong Kong and the GBA is underway, with first patient enrolment anticipated in the near term.
- **Scientific Exchange and Convening:** GBAICTI, BAY TRIAL and HHP will explore co-organising conferences, forums and professional exchange activities to promote dialogue among clinicians, researchers, regulators and industry stakeholders, and to support the sharing and dissemination of emerging research findings and clinical insights.

- **Talent and Capability Development:** The parties will explore opportunities to jointly advance training programmes, workshops and knowledge-sharing initiatives aimed at strengthening clinical research capabilities and developing talent pipelines in Hong Kong and the GBA.

Professor Bernard Cheung, Chief Executive Officer of GBAICTI, said: “We are pleased to collaborate with HHP through the 'One Institute One Center' framework between GBAICTI and BAY TRIAL. By leveraging GBAICTI’s role as a connector and facilitator, we aim to support high-quality clinical research and foster greater collaboration across the GBA. Following the signing of the MoU, together with BAY TRIAL, we look forward to supporting HHP’s upcoming multi-centre research activities as part of our broader effort to strengthen Hong Kong’s clinical trial ecosystem.”

Dr. Li Yichong, Director of BAY TRIAL, said: “We are excited to participate in this strategic collaboration with GBAICTI and HHP. By combining the strengths of Hong Kong and the Greater Bay Area, this partnership will advance high-quality, multi-centre clinical research and support the development of innovative medicines. BAY TRIAL remains committed to strengthening clinical trial networks and facilitating cross-boundary collaboration. We believe this MoU will enhance the region’s competitiveness in clinical research and reinforce the Greater Bay Area’s position as a leading hub for biomedical innovation.”

Dr. Dennis Lam, Founder of HHP, said: “We are delighted to partner with GBAICTI and BAY TRIAL. HHP plans to conduct multiple international Phase III clinical trials in Hong Kong and the GBA, leveraging Hong Kong to bring the strengths of China’s clinical research ecosystem to the global stage. With its world-class healthcare infrastructure, rigorous data standards and unique role as a ‘super connector’ between Chinese Mainland and global markets, Hong Kong is a highly attractive location for international clinical research. The “One Institute One Center” framework provides vital support to us as a homegrown start-up biopharmaceutical company.”

This MoU underscores a shared commitment to strengthening Hong Kong’s role as a regional hub for clinical research and a gateway for multi-centre trials. The parties will continue to explore opportunities for collaboration under this framework, with specific initiatives to be defined in due course.

###

Media Enquiries

Greater Bay Area International Clinical Trial Institute (GBAICTI) and Greater Bay Area International Clinical Trials Center (BAY TRIAL)

Samantha Wong

Director, Global Communications & Engagement

Email: samantha.wong@gbaicti.hk Tel: +852 5366 1368

Health Hope Pharma (HHP)

Chapman Chan

Chief Financial Officer

Email: Chapman.Chan@healthhopepharma.com